original articles introduction
|
|
- Nathan Barker
- 5 years ago
- Views:
Transcription
1 Annals of Oncology : 7, doi:.9/annonc/mdr Published online October Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases F. Saad *, J. E. Brown, C. Van Poznak, T. Ibrahim, S. M. Stemmer, A. T. Stopeck 6, I. J. Diel 7, S. Takahashi 8, N. Shore 9, D. H. Henry, C. H. Barrios, T. Facon, F. Senecal, K. Fizazi, L. Zhou, A. Daniels 6, P. Carrière 6 & R. Dansey 7 Department of Urology, University of Montreal Montreal, Canada; Cancer Research UK Clinical Centre, University of Leeds, Leeds, UK; Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, USA; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel; 6 Department of Medicine, University of Arizona, Arizona Cancer Center, Tucson, USA; 7 Institute for Gynecologic Oncology, Center for Comprehensive Gynecology, Mannheim, Germany; 8 The Cancer Institute Hospital of JFCR, Tokyo, Japan; 9 Carolina Urologic Research Center, Myrtle Beach; Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, USA; Internal Medicine Department, Pontifıćia Universidade Cato lica do Rio Grande do Sul School of Medicine, Rio Grande do Sul, Brazil; Department of Blood Diseases, Hoˆpital Claude Huriez, Lille, France; Northwest Medical Specialties Tacoma, USA; Department of Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Global Biostatistical Sciences; 6 Global Safety; 7 Clinical Development, Amgen Inc., Thousand Oaks, USA Received 9 May ; revised August ; accepted 9 August Background: Osteonecrosis of the jaw (ONJ) has been reported in patients receiving bisphosphonates for metastatic bone disease. ONJ incidence, risk factors, and outcomes were evaluated in a combined analysis of three phase III trials in patients with metastatic bone disease receiving antiresorptive therapies. Patients and methods: Patients with bone metastases secondary to solid tumors or myeloma were randomly assigned to receive either s.c. denosumab ( mg) or i.v. zoledronic acid ( mg) every weeks. On-study oral examinations were conducted by investigators at baseline and every 6 months. Oral adverse events were adjudicated by an independent blinded committee of dental experts. Results: Of 7 patients enrolled, 89 (.6%) patients were determined to have ONJ: 7 (.%) received zoledronic acid and (.8%) received denosumab (P =.). Tooth extraction was reported for 6.8% of patients with ONJ. ONJ treatment was conservative in >9% of patients. As of October, ONJ resolved in 6.% of patients (9.7% for zoledronic acid and.% for denosumab). Conclusions: In this combined analysis of three prospective trials, ONJ was infrequent, management was mostly conservative, and healing occurred in over one-third of the patients. Educating physicians about oral health before and during bone-targeted therapy may help reduce ONJ incidence and improve outcomes. Key words: bone metastases, denosumab, osteonecrosis of the jaw, zoledronic acid introduction *Correspondence to: Prof. F. Saad, Department of Urology, University of Montreal Hospital Center, 6 Sherbrooke East, Montreal, Quebec, Canada HL M. Tel: (ext. 766); Fax: ; fred.saad@umontreal.ca Osteonecrosis of the jaw (ONJ) was first reported in patients with a broad range of cancers receiving chemotherapy and i.v. bisphosphonates in the early s. In retrospective studies, the incidence of ONJ has been reported to occur with variable frequency [ 9]. A recent meta-analysis reported a mean incidence of ONJ of 6.% in these patients []. Recent guidelines issued by the American Academy of Oral and Maxillofacial Surgeons (AAOMS) define bisphosphonaterelated ONJ as an area of exposed bone in the jaw persisting for >8 weeks in patients without prior craniofacial radiation to the jaws [, ]. Symptoms of ONJ include pain, swelling and infection of soft tissues, loosening of teeth, drainage, and a feeling of heaviness or numbness in the jaw. Current recommendations by AAOMS are that ONJ be managed conservatively through the use of antibiotics, oral rinses, and limited debridement. More aggressive treatment, including surgery and bone resection, may be needed in patients with more severe stages of ONJ [ ]. Previous studies have attempted to identify both local and systemic risk factors associated with the development of ONJ in an advanced cancer population with bone metastases receiving antiresorptive therapy. Local risk factors, such as invasive ª The Author. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please journals.permissions@oup.com
2 dental procedures (e.g. tooth extraction) or concomitant oral disease, may increase the risk of ONJ [,, ]. Indeed, ONJ often occurs at the site of the procedure, although cases can occur spontaneously without a precipitating oral event [6, 7]. Epidemiology reports and retrospective studies have described multiple factors potentially associated with the development of ONJ, including chemotherapeutic agents, comorbid conditions (e.g. diabetes and anemia), and possibly, exposure to antiangiogenic agents [8, 9, 6 9]. Studies suggest that the risk of ONJ may increase with the potency of the antiresorptive agent and duration of treatment [,,,,, 8, ]. ONJ is more common in patients receiving i.v. than oral bisphosphonates []. The incidence of ONJ may vary by type of primary cancer, with higher incidence reported in patients with multiple myeloma or metastatic breast cancer [, ]. While the precise etiology of ONJ is unknown, leading hypotheses include impaired bone repair, suppression of osteoclast activity, infection and inflammation, and impaired angiogenesis or vascular repair [ ]. The incidence of ONJ was collected prospectively from 7 patients with metastatic bone disease enrolled in three registrational trials comparing the efficacy and safety of denosumab (XGEVAä; Amgen Inc., Thousand Oaks, CA) with zoledronic acid (ZometaÒ; Novartis Pharmaceuticals Corporation, East Hanover, NJ). For these studies, ONJ was predefined as a lesion in the oral cavity of exposed alveolar or palatal bone where gingival or alveolar mucosa is normally found, associated with nonhealing after appropriate care for 8 weeks in a patient without prior history of radiation to the head, face, or mouth. Data from these trials were used to define the incidence, risk factors, and outcomes of ONJ in this study population. patients and methods patients Patients (N = 7) with bone metastases and solid tumors or multiple myeloma were enrolled in one of three identically designed phase III, parallel, double-blind double-dummy trials [ 7]. These trials compared the efficacy of denosumab (s.c., mg) given every weeks (QW) with zoledronic acid (i.v., mg, adjusted for renal function) QW. A key secondary objective of these trials was to assess the safety and tolerability of denosumab compared with zoledronic acid. The identical designs of these trials allowed the data from each to be pooled and analyzed at a patient level. Eligible patients were 8 years old with histologically or cytologically confirmed solid tumors or myeloma and radiographic evidence of one or more bone metastases or osteolytic lesions. Patients with prior exposure to oral or i.v. bisphosphonates for treatment of advanced cancer were excluded, but prior treatment with oral bisphosphonates for other bone loss conditions (e.g. osteoporosis) was permitted. Additionally, patients with prior history or current evidence of ONJ or osteomyelitis of the jaw; an active dental or jaw condition requiring surgery; planned invasive dental procedures over the course of study; or nonhealed oral or dental surgery were excluded from these trials. Investigators were educated on the signs and symptoms of ONJ at study initiation and were provided additional training on carrying out detailed oral examinations for the purpose of evaluating ONJ. A visual examination of the oral cavity, including the teeth, mucosa, and jaws, was conducted by study investigators at screening and every 6 months while the patient was on study. Patients provided written informed consent before any study-related procedures were carried out. These studies were approved by the institutional review board or ethics committee at each site. identification of potential cases of ONJ Potential ONJ events were identified by a number of mechanisms including spontaneously reported cases of ONJ by investigators, regularly carried out automated searches of clinical and safety databases using a predefined list of 6 Medical Dictionary for Regulatory Activities (MedDRA)-preferred terms (supplemental data, available at Annals of Oncology online), and clinical review of all adverse oral events. The terms included on the MedDRApreferred terms list were discussed during by an oncology drug advisory committee [8], and additional terms were added in consultation with the ONJ Adjudication Committee (ONJAC). Once a reported adverse oral event was considered to be a potential ONJ event, the investigator was notified and queried for further clinical information. All available relevant information required to facilitate adjudication decisions was collected including dental records, radiographs, and imaging reports; photographs or progress notes describing the event; and discharge summaries. For patients with positively adjudicated ONJ, follow-up on the status of ONJ was collected every months until ONJ resolved or the patient withdrew consent or died. adjudication committee and process The ONJAC was an external independent panel of dental health care specialists who are experts in the field of and treatment. The ONJAC was blinded to treatment assignment and was responsible for reviewing and adjudicating all conditions identified as suspicious for ONJ. All cases referred to the ONJAC were reviewed by two adjudicators; if their opinion was discordant, the case was sent to a third adjudicator for a majority decision. data analysis To assess the relative importance of potential risk factors, patients with positively adjudicated ONJ were compared with patients without ONJ. Data for patients with ONJ included information solicited from the sites after as outlined above as well as data collected in the clinical trials database. Data for patients without ONJ were collected in the clinical trials database only. Systemic risk factors evaluated included comorbid conditions and concomitant therapies previously associated with ONJ development. Health-related quality of life (HRQoL) was evaluated using the Brief Pain Inventory-Short Form (BPI-SF) [9] and the general version of the Functional Assessment of Cancer Therapy (FACT-G) survey. The incidence of ONJ was assessed through the end of the primary analysis cutoff date for each of the three studies [6 March 9 (breast cancer), April 9 (other solid tumors and myeloma), and October 9 (prostate cancer)]. ONJ treatments and outcomes are reported through October. The Cochran Armitage test [] was used to evaluate the difference in ONJ incidence between treatment groups. The cumulative incidence of ONJ is presented as a histogram. The frequency and percentage of ONJ are provided by baseline demographics, systemic risk factors, oral events, and location. The impact of ONJ on HRQoL was assessed from 6 months before to the end of study or primary cut-off date, whichever occurred first. To evaluate the benefit risk of denosumab compared with zoledronic acid, the number of patients needed to treat (NNT) to prevent a skeletalrelated event (SRE) and the NNT to experience an ONJ event (number needed to harm) were calculated for denosumab in comparison with zoledronic acid. results Annals of Oncology Study durations (first enrollment date to primary analysis cutoff date) ranged from to months. For the overall study Saad et al. Volume No. May
3 population, the median (Q, Q) time on study was. (., 9.) months for patients in the zoledronic acid group and.6 (.6, 9.) months for patients in the denosumab group. The median (Q, Q) number of doses of active product received was. (., 9.) for patients randomly assigned to receive zoledronic acid and. (6.,.) for patients randomly assigned to receive denosumab. The fewer doses of zoledronic acid received by patients were primarily because of dose withholding due to increased serum creatinine levels. number of adjudicated cases and baseline demographics Overall, 87 oral adverse events from 76 (.8% of the overall population) patients were referred to the adjudication committee: 89 (approximately one-third) patients referred for adjudication (.6% of the overall patient population) had positively adjudicated ONJ (Figure ). Among patients with positively adjudicated ONJ, 7 (.%) were in the zoledronic acid group and (.8%) were in the denosumab group. The cumulative incidence of ONJ was not significantly different between treatment groups (P =.; Figure ). ONJ occurred from up to months after patients received the first dose of study drug. The median time of drug exposure before ONJ was months for both treatment groups. Baseline characteristics of patients with ONJ were similar to those of patients without ONJ and reflected those of the overall trial population (Table ). systemic risk factors Similar percentages of patients with ONJ and without ONJ had anemia, diabetes, or received chemotherapy (Table ). A slightly greater proportion of patients with ONJ than those without received corticosteroids, while this proportion was higher for patients receiving antiangiogenic agents (bevacizumab, sunitinib malate, and sorafenib), although only a small number of ONJ patients were exposed to the latter (n = ). associated oral events Among patients with ONJ, jaw pain was reported in nearly three-quarters, tooth extractions were reported for nearly twothirds, and coinciding oral infections were reported for nearly one-half (Table ). The mandible was the most common site of ONJ, while ONJ was observed less frequently in the maxilla. In a small number of patients (<%), ONJ was observed in both the mandible and the maxilla. patient-reported outcomes Data from the BPI-SF indicated that pain at worst, pain severity, and pain interference were stable over time in patients with ONJ (Figure A C). In addition, the mean FACT-G overall and subscale scores did not change over time in patients with ONJ (Figure D; data not shown). The instability in pain and quality-of-life scores at later time points was because few patients remained on study at the later time points. treatments, outcomes, and resolution All patients with positively adjudicated ONJ received care for ONJ from a dental health expert. Over half of patients with Positively Adjudicated ONJ n = 89 ZA n = 7 Patients With an Oral Event Identified as Potential ONJ N = 76 Negatively Adjudicated n = 87 n = All Patients N = 7 Patients Without an Oral Event N = 7 Figure. CONSORT diagram. Outcome of ONJ adjudication process. CONSORT, Consolidated Standards of Reporting Trials; ONJ, osteonecrosis of the jaw. Percentage of Subjects.%.8%.%.8% Zoledronic Acid.%.8% Month - Month - Month - 6 Figure. Cumulative incidence of ONJ. The crude incidence of ONJ reported for month,, and 6. positively adjudicated ONJ (%) were treated conservatively for ONJ (oral monitoring, oral rinses, and/or antibiotics). Approximately % of patients with ONJ underwent limited surgery, which included sequestrectomy, extraction, or debridement (Table ). Only four patients (<%) underwent resection of the affected bone. Of these patients, two had resolution of ONJ, one was lost to follow-up, and one had ONJ until death. In 6% of patients with positively adjudicated ONJ, ONJ was either ongoing, present at the time of death, or the outcome was unknown as of October (Table ). Resolution of ONJ occurred in 6.% ( of 89) of patients [9.7% ( of 7) for zoledronic acid;.% ( of ) for denosumab] as of this date. Among the patients who had resolution of ONJ, (78.%) discontinued blinded treatment, while 7 (.9%) Volume No. May doi:.9/annonc/mdr
4 Annals of Oncology Table. Baseline demographics Table. Oral events and location of ONJ Patients with ONJ (N = 89) Patients without ONJ (N = 6) Age, years (median) Sex, male (%).9. Race, n (%) White or Caucasian 77 (86.) 77 (8.) Black or African American 7 (7.9) 66 (.9) Hispanic or Latino () (.) Other a (.6) 6 (7.6) Geographic region, n (%) Europe (9.) 6 (.) North America 6 (9.) (9.) Latin America (.) 7 (7.9) Other b 7 (7.9) (9.) Primary tumor type, n (%) Breast (8.) (.7) Prostate (8.) 867 (.) Other solid tumor (6.9) c 97 (8.) Multiple myeloma 6 (6.7) 7 (.) a Other includes patients who self-identified as American Indian or Alaska Native; Asian, Japanese, native Hawaiian, or other Pacific Islander; or other. b Other includes Australia, India, Japan, New Zealand, and South Africa. c Other solid tumor includes non-small-cell lung cancer (n = 6), renal (n = 6), endometrial (n = ), gastric (n = ), or rectal (n = ). Table. Systemic risk factors Systemic risk factors Patients with ONJ (N = 89) Patients without ONJ (N = 6) Comorbid conditions, n (%) Anemia (Hg < g/dl) (.9) (.9) Diabetes (.) 87 (.) Other drugs, n (%) Corticosteroids a 6 (7.) (6.) Chemotherapy agents 6 (7.8) 87 (68.7) Antiangiogenics b (.7) (8.) a Excludes ocular and inhaled preparations. b Includes bevacizumab, sunitinib malate, and sorafenib. received one or more active doses of drug after diagnosis of ONJ. Among these seven patients who received one or more active doses after diagnosis of ONJ, one was in the zoledronic acid group and six were in the denosumab group. No patients received continuous uninterrupted treatment from the time of diagnosis to resolution of ONJ. benefit risk assessment of denosumab treatment In these studies, more patients experienced SREs (.% overall) than ONJ (.6% overall). When compared with zoledronic acid,. patients need to be treated with denosumab for year to prevent additional patient from experiencing a first SRE. When multiple SREs are evaluated, only 6.7 patients need to be treated with denosumab for year to prevent one additional SRE compared with zoledronic acid. In contrast,. patients need to be treated with denosumab for year to incur one more event of ONJ compared with zoledronic acid. The benefit of denosumab in preventing an SRE compared with zoledronic acid outweighs the risk of ONJ by a factor of 7. discussion Zoledronic acid (N = 7) (N = ) All (N = 89) Oral event a, n (%) Tooth extraction (6.9) (9.6) (6.8) Coinciding oral infection 7 (.9) 6 (.) (8.) Jaw pain (67.6) 8 (9.) 7 (8.) Location of ONJ, n (%) Mandible (8.8) (6.) 6 (7.) Maxilla (.) (8.8) (.) Both (.7) (.8) (.) a Tooth extraction reported during the study; jaw pain and oral infection noted either before or at the time ONJ was diagnosed. Initial reports of ONJ suggested a highly morbid and untreatable condition []. Over the past several years, a better understanding of the natural history of ONJ has developed, and it is now recognized that ONJ can present with a range of severities and can frequently resolve. As experience with diagnosis and management of ONJ has emerged, the plan of care has become focused on conservative measures. Whereas the initial medical management of ONJ typically involved more aggressive surgical intervention [], it has evolved to a less invasive interventional approach as awareness of the condition has increased. In agreement with published reports [, 7,, ], tooth extraction in this analysis of prospective studies was the predominant oral factor associated with the development of ONJ. This finding emphasizes the importance of assessing oral health of patients and implementing preventive dentistry if necessary before initiating therapy. Two recent studies showed that the incidence of ONJ decreased after routine preventive dental measures were implemented [, ]. Once antiresorptive therapy has been initiated, the aim should be maintenance of good oral health and avoidance of elective extractions as recommended by AAOMS and European Medicines Agency (EMA) [, ]. The association of systemic risk factors with ONJ was less pronounced than the association observed with oral factors. There was some association of ONJ with the use of corticosteroids and a near doubling of cases of ONJ in association with the use of antiangiogenic agents but no association with the use of chemotherapeutic agents, anemia, or diabetes. Antiangiogenic agents may potentially contribute to the development of ONJ by inhibiting vascular repair of the frequent microdamage sustained by the jaw. However, a recent analysis of ONJ incidence in patients with breast cancer Saad et al. Volume No. May
5 A B Pain at Worst (Mean +/- SD) Pain Severity (Mean +/- SD) C Pain Interference (Mean +/- SD) D FACT-G Total Score (Mean +/- SD) Figure. Patient-reported changes in pain and among patients with positively adjudicated ONJ. (A) Pain at worst; (B) pain severity; (C) pain interference; and (D) FACT-G total score. Data shown are the mean (SD) of patient-reported levels of pain (A C) or HRQoL (D) at monthly intervals from 6 months before diagnosis of ONJ up to the time the patient discontinued the study for patients with positively adjudicated ONJ. HRQoL, health-related quality of life; FACT-G, Functional Assessment of Cancer Therapy - General; SD, standard deviation; and bone metastases found no association between development of ONJ and exposure to these agents [6]. The immunosuppressant effects of corticosteroids may slow wound healing and alter the oral microflora, thus increasing the risk of oral infection and ONJ. It is unclear if demographic factors are associated with ONJ [, 8,,, 8, ], and they were not associated with ONJ in this analysis. As the vast majority of patients in these studies were white and nearly three-quarters of patients were enrolled in the United States or Europe, any differences in ONJ incidence by race or geographic region could not be interpreted. Pain and HRQoL levels were stable from baseline over time in patients who developed ONJ. These data suggest that ONJ did not noticeably impact patients HRQoL. It should be noted that the instruments used in these studies are limited by not being specifically designed to capture oral events. An important goal for physicians who are treating patients with metastatic bone disease with antiresorptive agents is to minimize the complications of this beneficial therapy including reducing the occurrence and severity of ONJ. The investigators for these trials were educated on the signs and symptoms that are indicative of potential development of ONJ and were also educated to treat active oral conditions before enrollment. Additionally, the patients had frequent and regular on-study oral examinations carried out by study investigators. As such measures could have either prevented ONJ to develop or resulted in earlier detection of ONJ, this suggests that these practices should be considered part of the standard of care in routine practice. Volume No. May doi:.9/annonc/mdr
6 Table. ONJ treatment and outcomes Zoledronic acid (N = 7) (N = ) All (N = 89) Treatment, n (%) Limited surgery 6 (.) (.) 7 (.6) Sequestrectomy (.) (9.) (6.8) Extraction (8.) (9.6) 8 (9.) Debridement (8.) (.8) 6 (6.7) Curettage (.7) (.8) (.) Other a (.8) (.9) (.6) Bone resection (.7) (.8) (.) Outcomes b, n (%) Present at time of death (.) (8.) (9.) Ongoing 8 (.6) 8 (.) 6 (8.) Unknown (8.) (.8) 6 (6.7) Resolved c (9.7) (.) (6.) Median (range) time to resolution, months 8.7 (.7 8.) 8. (..6) 8. (..6) a Other includes bone grinding, infundibulotomy, reduction in bone height, laser therapy, and sinusotomy. b As of October. c Resolved referred to complete mucosal coverage of exposed bone. If a patient develops ONJ, current recommendations are to treat ONJ conservatively and avoid additional invasive surgeries [, ]. Investigators were counseled on the conservative treatment approach, and indeed, most patients in these trials received conservative treatment. This may have lead to the overall ONJ resolution rate of 6% observed in these trials. The resolution rate was somewhat greater in the denosumab group (.%) as compared with the zoledronic acid group (9.7%). One possible explanation for the difference in resolution rates between the treatment groups may be related to the different mechanisms of action of these agents. selectively inhibits RANKL and the osteoclast inhibition caused by denosumab is reversible [7]. Bisphosphonates accumulate within bone and are released upon bone resorption, potentially recirculating to cause further suppressive effects on osteoclast function [8]. Currently, no evidence exists that discontinuing antiresorptive therapy improves the outcome of ONJ [9 ]. As all patients with positively adjudicated ONJ stopped antiresorptive therapy for a period of time, this analysis is unable to shed further light on this question. One of the strengths of this analysis is that this is the first prospective evaluation of ONJ in patients with a broad spectrum of advanced cancer types using a large dataset from randomized phase III trials of antiresorptive agents. Also, rigorous processes were in place to capture and identify ONJ; this is clear from the high number of events referred to the ONJAC compared with those ultimately judged positive for ONJ. For these reasons, it is possible to have a high level of confidence in the accuracy of the incidence data. In summary, this prospective analysis provides assessment of ONJ incidence, risk factors, and outcomes in the context of current therapies used to treat patients with advanced cancer. In these studies, ONJ was an infrequent event, and the incidence of ONJ did not significantly differ between the zoledronic acid and denosumab treatment groups. Most patients who developed ONJ had associated oral events, including jaw pain, tooth extraction, coinciding oral infection, or systemic risk factors such as the use of corticosteroids or antiangiogenic agents. It is possible that the incidence and severity of ONJ were minimized in these studies through proactive education of investigators. This would suggest that with wider education of health care providers about the need to resolve outstanding dental issues before administration of antiresorptive therapy, as well as training on the recognition of the signs and symptoms of ONJ, a lower incidence of ONJ and resolution of ONJ with conservative treatments may be achieved. acknowledgements Amy Foreman-Wykert (Amgen Inc.) provided medical writing support. funding Amgen Inc. disclosure F. Saad currently conducts research for and has served as an advisor for Amgen Inc. JEB has received fees for speaking from Amgen Inc. and Novartis; received research funding from Novartis; consultant fees and a travel grant from Amgen Inc. and Roche; and fees for participation on an advisory board from Amgen Inc., Novartis, and Bristol-Myers Squibb. CVP has served on an advisory board for Amgen Inc. and has received research funding from Amgen Inc. and Novartis. TI has served as an advisor for Amgen Inc. and Novartis. ATS has received consulting fees from Amgen Inc. and Novartis. NS currently conducts research sponsored by Amgen Inc. and is an advisor for Amgen Inc. DHH currently conducts research sponsored by Amgen Inc. and is a member of the speakers bureau for Amgen Inc. KF has participated in advisory boards and as a speaker at symposium sponsored by Amgen Inc. and Novartis. LZ, AD, PC, and RD are employed by and own stock or stock options in Amgen Inc. SMS, IJD, ST, CHB, TF, and F. Senecal have no conflicts of interest to declare. references Annals of Oncology. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol ; : Cafro AM, Barbarano LA, Andriani A et al. Osteonecrosis of the jaw associated with chronic bisphosphonates therapy: an Italian experience. Blood (ASH Annual Meeting Abstracts) ; 6: (Abstr ).. Dimopoulos MA, Kastritis E, Anagnostopoulos A et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 6; 9: Dimopoulos MA, Kastritis E, Moulopoulos LA et al. The incidence of osteonecrosis of the jaw (ONJ) in patients with multiple myeloma who receive 6 Saad et al. Volume No. May
7 biphosphonates depends on the type of biphosphonate. Blood (ASH Annual Meeting Abstracts) ; 6: (Abstr 67).. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med ; : Pozzi S, Marcheselli R, Sacchi S et al. Analysis of frequency and risk factors for developing bisphosphonate associated osteonecrosis of the jaw. Blood (ASH Annual Meeting Abstracts) ; 6: (Abstr 7). 7. Tosi P, Zamagni E, Cangini D et al. Bisphosphonates and osteonecrosis of the jaws: incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid. Blood (ASH Annual Meeting Abstracts) ; 6: (Abstr 6). 8. Zervas K, Verrou E, Teleioudis Z et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in patients. Br J Haematol 6; : Aragon-Ching JB, Ning YM, Chen CC et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 9; 7: 6.. Migliorati CA, Woo SB, Hewson I et al. A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer ; 8: Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 7; 6: Ruggiero SL, Dodson TB, Assael LA et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws 9 update. J Oral Maxillofac Surg 9; 67:.. European Medicines Agency. CHMP Assessment Report on Bisphosphonates and Osteonecrosis of the Jaw. London: EMA/CHMP. ; europa.eu/docs/en_gb/document_library/other///wc8.pdf ( April, date last accessed).. Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 6; : Hoff AO, Toth BB, Altundag K et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 6; (8s): Herbozo PJ, Briones DL, Ferres AJ, Torrealba RL. Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 7; 6: Bagan JV, Jimenez Y, Murillo J et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of cases. Oral Oncol 6; : Jadu F, Lee L, Pharoah M et al. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 7; 8: Van Poznak C. Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Res Treat ; : Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 6; : King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 8; 8: Cavanna L, Berte R, Arcari A et al. Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature. Eur J Intern Med 7; 8: 7.. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg ; 6: Mashiba T, Mori S, Burr DB et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab ; (Suppl): 6.. Fizazi K, Carducci M, Smith M et al. A randomised, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in men with castration-resistant prostate cancer. Lancet ; 77: Henry DH, Costa L, Goldwasser F et al. A randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol ; 9:. 7. Stopeck AT, Lipton A, Body JJ et al. compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol ; 8: Department of Health and Human Services, Food and Drug Administration, Oncologic Drugs Advisory Committee. Gaithersburg, MD: Department of Health and HumanServices,FoodandDrugAdministration.; dockets/ac/cder.html#oncologicdrugs ( April, date last accessed). 9. Cleeland C. Pain assessment in cancer. In Osoba D (ed): Effect of Cancer on Quality of Life. Boca Raton, FL: CRC Press 99; 9.. Dmitrienko A, Molenberghs G, Chuang-Stein C, Offen W. Analysis of Clinical Trials Using SAS: A Practical Guide. Cary, NC: SAS Institute.. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg ; 6: 7.. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 6 cases. J Oral Maxillofac Surg ; 6: 7.. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 7; 6:.. Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 9; : 7.. Ripamonti CI, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 9; : Guarneri V, Miles D, Robert N et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat ; : Bekker PJ, Holloway DL, Rasmussen AS et al. A single-dose placebo-controlled study of AMG 6, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res ; 9: Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 7; 9 (Suppl ): S S6. 9. American Dental Association. Report of the Council on Scientific Affairs: Dental Management of Patients Receiving Oral Bisphosphonate Therapy Expert Panel Recommendations. ; pdfs/topics_osteonecrosis_bisphosphonate_report.pdf ( April, date last accessed).. Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc 9; : Patel V, McLeod NM, Rogers SN, Brennan PA. Bisphosphonate osteonecrosis of the jaw a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention. Br J Oral Maxillofac Surg ; 9: 7. Volume No. May doi:.9/annonc/mdr 7
THE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 119 No 1246 ISSN 1175 8716 Osteonecrosis of the jaw and bisphosphonates putting the risk in perspective Mark Bolland, David Hay, Andrew Grey, Ian Reid, Tim Cundy Abstract
More informationTitle: Osteoporosis and bisphosphonates related osteonecrosis of the jaw bone
Title: Osteoporosis and bisphosphonates related osteonecrosis of the jaw bone Authors: Alessandro Villa 1, Stefano Castiglioni 1, Alessandro Peretti 1, Marco Omodei 1, Giovanni B Ferrieri 1, Silvio Abati
More informationOsteoporosis Medications and Oral Health
Osteoporosis Medications and Oral Health Oral Health Topics Overview There are approximately 10 million Americans aged 50 years or older with osteoporosis and an additional 34 million with low bone mass
More informationCara B. Gonzales, DDS, PhD. Assistant Professor Department of Comprehensive Dentistry UTHSCSA Dental School
Cara B. Gonzales, DDS, PhD Assistant Professor Department of Comprehensive Dentistry UTHSCSA Dental School March 30, 2010 1 st annual STOHN Convocation 16 Community Clinicians 15 Investigators Bisphosphonate-associated
More informationDental Issues In Cancer Patients Using Bone Modifying Agents What Every GPO Must Know
Dental Issues In Cancer Patients Using Bone Modifying Agents What Every GPO Must Know Dr. Allan Hovan, DMD, MSD, FRCD (C) 2016 CAGPO Annual Meeting Four Seasons Hotel, Vancouver, B.C. Sunday, October 2
More informationProduct: Denosumab (AMG 162) Abbreviated Clinical Study Report: (Extension Phase Results) Date: 24 August 2010 Page Page 2 of 2 of
Product: Denosumab (MG 162) bbreviated Clinical Study Report: 20040114 (Extension Phase Results) Date: 24 ugust 2010 Page Page 2 of 2 of 1314 55 2. SYNOPSIS Name of Sponsor: mgen Inc. Name of Finished
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationManagement of Bone Metastasis in Breast Cancer: Drugs, Dosing and Duration
Management of Bone Metastasis in Breast Cancer: Drugs, Dosing and Duration Kara Laing, MD, FRCPC Chair and Associate Professor, Discipline of Oncology Memorial University of Newfoundland Medical Oncologist,
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationGuidelines for the diagnosis of bisphosphonate-related
Mini-review Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ) Salvatore L. Ruggiero Assistant Professor Department of Oral and Maxillofacial Surgery Stony Brook School
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 11 April 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 11 April 2012 XGEVA 120 mg, solution for injection 1 glass vial of 120 mg/1.7 ml (CIP code: 217 253-8) 4 glass vials
More informationBisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons
Bisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons ALIYA A. KHAN, LORENA P. RIOS, GEORGE K.B. SÁNDOR, NAZIR KHAN, EDMUND PETERS, MOHAMMED O. RAHMAN,
More informationBisphosphonates, inhibitors of osteoclasts, have
ABSTRACT Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy Strategies for prevention and early recognition MAICO D. MELO, D.M.D.; GEORGE OBEID, D.D.S. Bisphosphonates,
More informationMedication related osteonecrosis of the jaws. The first reported cases in the Baltic States and a literature review
CASE REPORTS SCIENTIFIC ARTICLES Stomatologija, Baltic Dental and Maxillofacial Journal, 17:89-96, 2015 Medication related osteonecrosis of the jaws. The first reported cases in the Baltic States and a
More informationMonitoring therapy and mitigating side effects
Monitoring therapy and mitigating g side effects Noopur Raje, MD Director, Center for Multiple Myeloma MGH Cancer Center Associate Professor of Medicine Harvard Medical School Issues with BP Therapy Renal
More informationScottish Medicines Consortium
Scottish Medicines Consortium zoledronic acid 5mg/100ml solution for infusion (Aclasta) No. (317/06) Novartis 8 September 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationOsteonecrosis of the Jaw in the United States Food and Drug Administration s Adverse Event Reporting System (FAERS)
ORIGINAL ARTICLE JBMR Osteonecrosis of the Jaw in the United States Food and Drug Administration s Adverse Event Reporting System (FAERS) Xiaoyan Zhang, 1 Issam S Hamadeh, 2,3 Shuang Song, 2 Joseph Katz,
More informationOsteonecrosis of the jaw (ONJ)
Osteonecrosis of the jaw (ONJ) This Infosheet explains what osteonecrosis of the jaw (ONJ) is, a rare condition related to long-term treatment with drugs known as bisphosphonates. What is ONJ? ONJ is a
More informationAbstract. Osteonecrosis of the jaw (ONJ)
ca Applied Research Cite this article as: J Can Dent Assoc 2010;76:aXXX 2011;77:b147 Preventive Strategies and Clinical Implications for Bisphosphonate-Related Osteonecrosis of the Jaw: A Review of 282
More informationUniversity Hospital of Cranio-, Maxillofacial and Oral Surgery, Medical University of Vienna, Vienna, Austria.
ORIGINAL ARTICLE TREATMENT RESULTS OF BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAWS Arno Wutzl, MD, DMD, Edwin Biedermann, MD, Felix Wanschitz, MD, DMD, PhD, Rudolf Seemann, MD, Clemens Klug, MD, DMD,
More informationIncidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates
Basic research Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates Marcin Kos Department of Maxillofacial Surgery, Klinikum Minden, Minden,
More informationApproved SYNOPSIS. Product: Denosumab (AMG 162) Interim Synopsis Clinical Study Report: Date: 23 July 2010.
Page 2 of 24012 SYNOPSIS Name of Sponsor: Amgen Inc Name of Finished Product: not applicable Name of Active Ingredient: denosumab (AMG 162) Title of Study: A Randomized, Double-Blind, Multicenter Study
More informationOSTEONECROSIS OF THE JAW BONES IN PATIENTS TREATED WITH BISPHOSPHONATES FOR MULTIPLE MYELOMA
CASE SERIES OSTEONECROSIS OF THE JAW BONES IN PATIENTS TREATED WITH BISPHOSPHONATES FOR MULTIPLE MYELOMA F A VOHRA, M A SHEIKH ABSTRACT Key words Bisphosphonates, particularly those administered through
More informationNon-commercial use only
Reumatismo, 2017; 69 (1): 9-15 Drug-induced osteonecrosis of the jaw: the state of the art A. Fassio 1, F. Bertoldo 2, L. Idolazzi 1, O. Viapiana 1, M. Rossini 1, D. Gatti 1 1 Department of Medicine, Rheumatology
More informationAmerican Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws
American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws Approved by the Board of Trustees September 25, 2006 Introduction Bisphosphonate-related
More informationS^t _j4 A-N.1^.^ A _ WE 2
S^t _j4 A-N.1^.^ A _ WE 2 Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to RANKL Title of Study: A Randomized Study
More informationla Cura dei Tumori, Meldola, Italy; b Oral Surgery and Dentistry Department, Otorhinolaryngology Unit, Morgagni Pierantoni Hospital, Forlì, Italy
The Oncologist Symptom Management and Supportive Care Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study TONI IBRAHIM, a FRANCESCA BARBANTI, b
More informationRipamonti C, et al. ASCO 2012 (Abstract 9005)
ZOOM: A Prospective, Randomized Trial of Zoledronic Acid for Long-term Treatment in Patients With Bone-Metastatic Breast Cancer After 1 Year of Standard Zoledronic Acid Treatment D. Amadori, M. Aglietta,
More informationAlessandria 23 Giugno Osteonecrosi dei mascellari (ONJ): Prevenzione, Diagnosi, Trattamento Update 2009
Alessandria 23 Giugno 2009 Osteonecrosi dei mascellari (ONJ): Prevenzione, Diagnosi, Trattamento Update 2009 ONJ anche se l osso non è esposto? Prof. Michele D. Mignogna, MD, DDS FEDERICO II UNIVERSITY
More informationMRI evaluation of bisphosphonate-related osteonecrosis of the jaw
MRI evaluation of bisphosphonate-related osteonecrosis of the jaw Poster No.: C-1949 Congress: ECR 2012 Type: Authors: Keywords: DOI: Scientific Paper G. Filonzi, A. Bazzocchi, P. Spinnato, E. Salzzoni;
More informationDENOSUMAB. . Peter Harper Guy s, King s & St Thomas & Leaders in Oncology Care (LOC) DENOSUMAB. RANK-L/Bisphosphonates; Bone secondaries & Lung Cancer
DENOSUMAB. Peter Harper Guy s, King s & St Thomas & Leaders in Oncology Care (LOC) DENOSUMAB RANK-L/Bisphosphonates; Bone secondaries & Lung Cancer. Peter Harper Guy s, King s & St Thomas & Leaders in
More informationFor the Patient: Bisphosphonates and Oral Health in Multiple Myeloma
For the Patient: Bisphosphonates and Oral Health in Multiple Myeloma Regular dental care is very important for all cancer patients. As soon as possible after your cancer diagnosis, your dentist should
More informationClinical Study Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients
International Dentistry Volume 2014, Article ID 427273, 7 pages http://dx.doi.org/10.1155/2014/427273 Clinical Study Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple
More informationBisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking
Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking Arezo Tardast, Reine Sjoman, Sigbjorn Loes and Jahan Abtahi Linköping University Post
More informationHOW I DO IT. Introduction. BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4):
HOW I DO IT How I Do It: Managing bone health in patients with prostate cancer Jack Barkin, MD Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How
More informationManaging Skeletal Metastases
Managing Skeletal Metastases Alison Stopeck, M.D. Professor of Medicine Director, Breast Cancer Program University of Arizona Cancer Center Tucson, AZ Disclosures: Consulting, research funding, and honoraria
More informationZerlinda (MRP DK/H/2265/001)
Zerlinda (MRP DK/H/2265/001) VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Prevention of bone complications, e.g. fractures, in adult patients with bone metastases (spread
More information2014 Update Revisions for: AAOMS Strategies for patient management with or at risk for medication-related osteonecrosis of the jaw:
AAOMS Strategies for patient management with or at risk for medication-related osteonecrosis of the jaw: 2007 2009 2014 2014 Update Revisions for: Diagnosis, Staging, Management strategies, (our main interest)
More informationManagement of Acute Oncological emergencies
Management of Acute Oncological emergencies Malignant Spinal cord compression (MSCC) Neutropenic sepsis Superior vena caval obstruction Hypercalcemia Hyponatremia Bowel obstruction Brain Metastasis with
More informationBone Metastases. Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital
Bone Metastases Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital 1 Outline Pathophysiology Signs & Symptoms Diagnosis Treatment Spinal Cord Compression 2 General Information
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 ACTONEL 5 mg, film-coated tablet B/14 (CIP code: 354 362-3) ACTONEL 30 mg, film-coated tablet B/28 (CIP
More informationOccurrence of Bisphosphonate-Related Osteonecrosis of the Jaw After Surgical Tooth Extraction
J Oral Maxillofac Surg 68:797-804, 2010 Occurrence of Bisphosphonate-Related Osteonecrosis of the Jaw After Surgical Tooth Extraction Giorgia Saia, MD,* Stella Blandamura, MD, Giordana Bettini, MD, Anita
More informationClosure of an Open Wound Associated with Bisphosphonate-Related Osteonecrosis of the Jaw in a Breast Cancer Patient
The Open Dentistry Journal, 2011, 5, 163-167 163 Open Access Closure of an Open Wound Associated with Bisphosphonate-Related Osteonecrosis of the Jaw in a Breast Cancer Patient Nafiseh Soolari 1 and Ahmad
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationFarmaci bone-targeted: basi biologiche e razionale d uso. Giovanni Pavanato Rovigo
Farmaci bone-targeted: basi biologiche e razionale d uso Giovanni Pavanato Rovigo DICHIARAZIONE Relatore: Giovanni Pavanato Come da nuova regolamentazione della Commissione Nazionale per la Formazione
More informationBone Health in the Cancer Patient. Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018
Bone Health in the Cancer Patient Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018 Overview Healthy bone is in a constant state of remodelling
More informationMRONJ: Medication-Related Osteonecrosis of the Jaw
MRONJ: Medication-Related Osteonecrosis of the Jaw Matthew McKnight DDS,MD History 2004, new reports of difficult to treat jaw osteonecrosis associated with bisphosphonates. Bisphosphonate-related Osteonecrosis
More informationIbandronate: Its Role in Metastatic Breast Cancer
Ibandronate: Its Role in Metastatic Breast Cancer David Cameron, a Marie Fallon, a Ingo Diel b a Western General Hospital, Edinburgh, United Kingdom; b Institute for Gynecological Oncology, Mannheim, Germany
More informationThe effects of osteoclast modifiers on the oral cavity: a review for prescribers
REVIEW C URRENT OPINION The effects of osteoclast modifiers on the oral cavity: a review for prescribers Matthew S. Epstein a, Joel B. Epstein b, and Hillel D. Ephros c,d Purpose of review Osteonecrosis
More informationThe Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer
City Wide Medical Oncology Rounds Friday Sept. 21 st, 2007 The Latest is the Greatest Future Directions in the Management of Patients with Bone Metastases from Breast Cancer Mark Clemons Head, Breast Medical
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationNovel therapies for Myeloma bone disease. Dr. Naif AlJohani ABIM,FRCPC Adult Hematology/BMT King Faisal specialist hospital & Research center Jeddah
Novel therapies for Myeloma bone disease Dr. Naif AlJohani ABIM,FRCPC Adult Hematology/BMT King Faisal specialist hospital & Research center Jeddah 1 Introduction Multiple myeloma (MM) is a plasma cell
More informationOSTEONECROSI DELLA MANDIBOLA
OSTEONECROSI DELLA MANDIBOLA OSTEONECROSIS OF THE JAWS (ONJ) Paolo Vescovi DDS, MSc Professore Associato di Clinica Odontostomatologica Direttore EMDOLA (European Master Degree on Oral Laser Applications)
More informationEfficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with Advanced Cancer
Review Articles Jpn J Clin Oncol 2012;42(8)663 669 doi:10.1093/jjco/hys088 Advance Access Publication 13 June 2012 Efficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with
More informationCommon Prescription mg/ day mg/ day mg/day
Table 19.1. Medical Management of Burning Mouth Syndrome Medications Examples of Agents Dosage Common Prescription Tricyclic antidepressants Amitryptyline (Elavil ) 10 150 mg/ day 10 mg at bedtime; increase
More informationEfficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data
Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data Richard Bell The Andrew Love Cancer Centre Cancer Services, Medical Oncology, Geelong, Victoria, Australia Key Words. Bisphosphonate
More informationPREVENTING BROKEN BONES:
PREVENTING BROKEN BONES: Your guide to understanding how XGEVA can help prevent broken bones and other serious bone problems* when cancer from solid tumors spreads to your bones.1 *Serious bone problems
More informationIs oral bisphosphonate therapy a risk factor for implant failure?
C L I N I C A L Is oral bisphosphonate therapy a risk factor for implant failure? Johan Hartshorne 1 A critical appraisal of a systematic review: Ata-Ali J, Ata-Ali F, Peñarrocha-Oltra D, Galindo-Moreno
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: denosumab_prolia_xgeva 3/2011 9/2017 9/2018 9/2017 Description of Procedure or Service Receptor activator
More informationBone metastases in hematology
Botziekte bij hematologische tumoren Prof. Dr. Michel Delforge Hematologie, UZ Leuven Bone metastases in hematology The bone marrow is the source of many hematological malignancies However, bone damage
More informationAnalysis of Denosumab on Skeletal-Related Events in Patients With Advanced Breast Cancer
Downloaded on 12 07 2018. Single-user license only. Copyright 2018 by the Oncology Nursing Society. For permission to post online, reprint, adapt, or reuse, please email pubpermissions@ons.org Online Exclusive
More informationBisphosphonate-Related Jaw Necrosis Part 1: Background, Incidence and Risk Factors
Quality Resource Guide MetLife designates this activity for 1.5 continuing education credit for the review of this Quality Resource Guide and successful completion of the post test. Bisphosphonate-Related
More informationUp to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed
Available online at www.sciencedirect.com British Journal of Oral and Maxillofacial Surgery 53 (2015) 13 17 Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents
More informationAntiresorptive Medications and Your Oral Health
Antiresorptive Medications and Your Oral Health This booklet focuses on preventing and managing oral complications that could arise from the use of antiresorptive medications in patients with cancer or
More informationGuidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION should be recommended
Guidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION Denosumab is suitable for patients with established osteoporosis for both primary and secondary fracture prevention
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationwileyonlinelibrary.com/journal/jop
J Oral Pathol Med (2012) 41: 222 228 ª 2011 John Wiley & Sons A/S Æ All rights reserved doi: 10.1111/j.1600-0714.2011.01095.x wileyonlinelibrary.com/journal/jop Multiple myeloma vs. breast cancer patients
More informationCurrent Management of Metastatic Bone Disease
Current Management of Metastatic Bone Disease Evaluation and Medical Management Dr. Sara Rask Head, Medical Oncology Simcoe Muskoka Regional Cancer Centre www.rvh.on.ca Objectives 1. Outline an initial
More informationEuropean Medicines Agency
European Medicines Agency EMEA/CHMP/292474/2009 EMEA/H/A-5(3)/1130 OPINION OF THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE PURSUANT TO ARTICLE 5(3) OF REGULATION (EC) No 726/2004, ON BISPHOSPHONATES
More informationDenosumab-related osteonecrosis of the jaw: A literature review Martwica kości szczęk wywołana denozumabem przegląd piśmiennictwa
Reviews Denosumab-related osteonecrosis of the jaw: A literature review Martwica kości szczęk wywołana denozumabem przegląd piśmiennictwa Gianfilippo Nifosì 1,A F, Antonio Fabrizio Nifosì 2,A F, Lorenzo
More informationBone Scans, Bisphosphonates, and a Lack of Acute Changes Within the Mandible
J Oral Maxillofac Surg 69:114-119, 2011 Bone Scans, Bisphosphonates, and a Lack of Acute Changes Within the Mandible Patrick G. Morris, MD,* Clifford Hudis, MD, Jorge Carrasquillo, MD, Steven Larson, MD,
More informationEffects of Bisphosphonates on the Jaw Bones
Effects of Bisphosphonates on the Jaw Bones Kugarubani Krishnan Final year B.D.S Student,Department Of Oral And Maxillofacial Surgery.Saveetha Dental College Dr. M.P.Santhosh Kumar M.D.S. * Reader,Department
More informationORAL MEDICINE. Editor: Craig S. Miller. Vol. 112 No. 2 August 2011
Vol. 112 No. 2 August 2011 ORAL MEDICINE Editor: Craig S. Miller Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center
More informationBisphosphonate-related osteonecrosi Titlein Japanese population: a case seri patients at our clinic. Nomura, T; Shibahara, T; Uchiyama,
Bisphosphonate-related osteonecrosi Titlein Japanese population: a case seri patients at our clinic. Nomura, T; Shibahara, T; Uchiyama, Shibui, T; Yakushiji, T; Watanabe, Author(s) Ogane, S; Murayama,
More informationBone Health in Patients with Multiple Myeloma
Bone Health in Patients with Multiple Myeloma Amrita Y. Krishnan, MD Director Judy and Bernard Briskin Myeloma Center City of Hope Comprehensive Cancer Center Bone Health Bisphosphonates in Space Bone
More informationXgeva. Xgeva (denosumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.18 Subject: Xgeva Page: 1 of 5 Last Review Date: March 16, 2018 Xgeva Description Xgeva (denosumab)
More informationBisphosphonate-induced Jaw Osteonecrosis (BJON) & its Management Strategy
Article ID: WMC002619 2046-1690 Bisphosphonate-induced Jaw Osteonecrosis (BJON) & its Management Strategy Corresponding Author: Dr. Vinod K Dayma, Senior Demonstrator, Dept. of Dental Anatomy and Histology,
More informationBisphosphonates and RANK-L inhibitors in Myeloma
Bisphosphonates and RANK-L inhibitors in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationBisphosphonate-induced Osteonecrosis of the Jaws: Review, Clinical Implications and Case Report
Head and Neck Pathol (2007) 1:156 164 DOI 10.1007/s12105-007-0022-5 CASE REPORT Bisphosphonate-induced Osteonecrosis of the Jaws: Review, Clinical Implications and Case Report Yusuf Farouk Suleman Æ Shabnum
More informationApproved. PASS INFORMATION Title
Date: 10 September 2015 Page 1 of 246 PASS INFORMATION Title Survey of Oncology Practitioners Prescribing XGEVA in Europe to Evaluate Their Knowledge of XGEVA Summary of Product Characteristics Pertaining
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationAmgen (Europe) GmbH, Zug, Switzerland, 2 Amgen GmbH, Munich, Germany, 3
Occurrence of skeletal-related events (SRE) in pa9ents with solid tumors (ST): early versus late ini9a9on of SRE preventa9ve agents (SPA) Intorcia M 1, Hohmann D 2, Giannopoulou C 1, Ansorge S 3, Diel
More informationClinical Specialist Statement Template
Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationMedication-related osteonecrosis of the jaw: Clinical and practical
J Int Soc Prev Community Dent. 2016 Mar-Apr; 6(2): 97 104. doi: 10.4103/2231-0762.178742 PMCID: PMC4820581 Medication-related osteonecrosis of the jaw: Clinical and practical guidelines Daniele Rosella,
More informationTalib A. Najjar, DMD, MDS, PhD Professor Oral & Maxillofacial Surgery Rutgers University
Talib A. Najjar, DMD, MDS, PhD Professor Oral & Maxillofacial Surgery Rutgers University 1 Biochemistry Interaction with Oral & Systemic Diseases Periodontal disease Jaw Bone Necrosis due to Bisphosphonate
More informationMedication Prior Authorization Form
Reclast (Zoledronic Acid) Policy Number: 1050 Policy History Approve Date: 12/11/2015 Revise Dates: 8/22/2016 Next Review: 12/11/2016 Review Dates: Preauthorization All Plans Benefit plans vary in coverage
More informationAppendix D Clinical specialist statement template
Denosumab for the treatment of bone metastases from solid tumours Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare
More informationMultiple systemic diseases complicated by bisphosphonate osteonecrosis: a case report
Case Report Multiple systemic diseases complicated by bisphosphonate osteonecrosis: a case report Fabrizio Carini, MD, DMD 1 Lorena Barbano, BDS 2 Vito Saggese, MDS 3 Dario Monai, MDS 3 Gianluca Porcaro,
More informationOsteonecrosis of the Jaw Onset Times Are Based on the Route of Bisphosphonate Therapy
PATHOLOGY J Oral Maxillofac Surg 71:513-519, 2013 Osteonecrosis of the Jaw Onset Times Are Based on the Route of Bisphosphonate Therapy Kenneth E. Fleisher, DDS,* Anu Jolly, Uma Deepthi Chippada Venkata,
More informationOsteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017
Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1
More informationXgeva. Xgeva (denosumab) Description. Section: Prescription Drugs Effective Date: January 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.18 Subject: Xgeva Page: 1 of 5 Last Review Date: December 3, 2015 Xgeva Description Xgeva (denosumab)
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 35 DECEMBER 10 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast
More informationReview Article. Doi: /jioh
Received: 03 rd March 2016 Accepted: 25 th June 2016 Conflicts of Interest: None Source of Support: Nil Review Article Doi: 10.2047/jioh-08-08-11 Antiresorptive Agent-induced Osteonecrosis of Jaw: An Enigma
More informationSevere osteonecrosis of the jaws in a compromised patient subjected to bisphosphonate therapy
PRESENTACIÓN DE CASO Severe osteonecrosis of the jaws in a compromised patient subjected to bisphosphonate therapy Osteonecrosis severa de los maxilares asociada al uso de bifosfonatos Juliana Dreyer de
More informationManaging Skeletal Metastases
School of Breast Oncology 2012 Managing Skeletal Metastases Cathy Van Poznak, MD Assistant Professor University of Michigan Comprehensive Cancer Center Saturday, November 3, 2012 Learning Objectives: Define
More informationXgeva (denosumab) injection, for subcutaneous use Initial US Approval: 2010
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XGEVA safely and effectively. See full prescribing information for XGEVA. Xgeva (denosumab) injection,
More information